Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Conclusions: In WISDOM, high screening blood eosinophil count (≥4% or ≥300 cells/µL) predicted an increased exacerbation risk in patients with severe to very severe COPD after ICS withdrawal.Funding: Boehringer Ingelheim. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Calverley, P. M. A., Wouters, E. F. M., Finnigan, H., Tetzlaff, K., Magnussen, H. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
LATE-BREAKING ABSTRACT: Safety of salmeterol/fluticasone propionate (FSC) compared to fluticasone propionate (FP) in 4-17 yr olds with asthma
Conclusion: No evidence of increased protocol-defined serious asthma events with FSC compared to FP in children 4-17yr was seen.Funding: GSK (115358, 115359). (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Stempel, D., Szefler, S., Pedersen, S., Zeiger, R., Mitchell, H., Liu, A., Raphiou, I., Kral, K., Yeakey, A., Buaron, K., Prillaman, B., Lee, L., Yun Kirby, S., Pascoe, S. Tags: 7.2 Paediatric Asthma and Allergy Source Type: research
Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial
For patients with well-controlled asthma, ‘step down’ of therapy is recommended. We evaluated Japanese patients switching from inhaled corticosteroid (ICS)/long-acting beta2-agonists (LABA; equivalent to fluticasone propionate [FP]/salmeterol [SAL] 250/50 μg twice daily [BD]) to fluticasone furoate (FF)/vilanterol (VI) 100/25 μg, th en stepping down to ICS alone. (Source: Respiratory Medicine)
Source: Respiratory Medicine - September 29, 2016 Category: Respiratory Medicine Authors: Mitsuru Adachi, Caroline Goldfrad, Loretta Jacques, Yoshie Nishimura Source Type: research
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study
The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).
AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. Patients were randomised (1:1) to aclidinium/formoterol 400/12 µg twice-daily via Genuair/Pressair or salmeterol/fluticasone 50/500 µg twice-daily via Accuhaler. The primary end-point was peak forced expiratory volume in 1 s (FEV...
Source: European Respiratory Journal - September 29, 2016 Category: Respiratory Medicine Authors: Vogelmeier, C., Paggiaro, P. L., Dorca, J., Sliwinski, P., Mallet, M., Kirsten, A.-M., Beier, J., Seoane, B., Segarra, R. M., Leselbaum, A. Tags: COPD and smoking Original Articles: COPD Source Type: research
High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
The high-strength formulation of extrafine beclometasone dipropionate/formoterol fumarate (BDP/Form) 200/6 µg has been developed to step up inhaled corticosteroid treatment, without increasing the dose of the bronchodilator, in patients who are not controlled with previous therapies. Two clinical studies have evaluated efficacy of high-strength BDP/Form as compared with another high-dose fixed combination and BDP monotherapy. Overall, data show that BDP/Form 200/6 μg improves lung function and has beneficial effects on symptoms, use of rescue medication and asthma control, with an acceptable safety profile compara...
Source: Therapeutic Advances in Respiratory Disease - September 19, 2016 Category: Respiratory Medicine Authors: Corradi, M., Spinola, M., Petruzzelli, S., Kuna, P. Tags: Reviews Source Type: research
Vilanterol and fluticasone furoate for asthma.
CONCLUSIONS: Some evidence suggests clear advantages for VI/FF, in combination, compared with placebo, particularly for forced expiratory volume in one second (FEV1) and peak expiratory flow; however, the variety of questions addressed in the included studies did not allow review authors to draw firm conclusions. Information was insufficient for assessment of whether once-daily VI/FF was better or worse than twice-daily FP/SAL in terms of efficacy or safety. It is clear that more research is required to reduce the uncertainties that surround interpretation of these studies. It will be necessary for these findings to be rep...
Source: Cochrane Database of Systematic Reviews - August 31, 2016 Category: Journals (General) Authors: Dwan K, Milan SJ, Bax L, Walters N, Powell C Tags: Cochrane Database Syst Rev Source Type: research
Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma
New England Journal of Medicine,Volume 375, Issue 9, Page 840-849, September 2016. (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - August 30, 2016 Category: Internal Medicine Authors: David A. Stempel Stanley J. Szefler S øren Pedersen Robert S. Zeiger Anne M. Yeakey Laurie A. Lee Andrew H. Liu Herman Mitchell Kenneth M. Kral Ibrahim H. Raphiou Barbara A. Prillaman Kathleen S. Buaron Suyong Yun Kirby Steven J. Pascoe Source Type: research
Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone Propionate Combination Therapy
Conclusions In this large retrospective pharmacy database analysis, patients using AirFluSal Forspiro were more likely to persist with treatment compared with those using Seretide Diskus as demonstrated by the overall survival experience of the 2 populations (12-month study period). These new data provide a basis for further research to better understand persistence behavior and to develop strategies to address poor persistence. (Source: The Journal of Allergy and Clinical Immunology: In Practice)
Source: The Journal of Allergy and Clinical Immunology: In Practice - August 30, 2016 Category: Allergy & Immunology Source Type: research
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis
Publication date: Available online 23 July 2016 Source:The Lancet Respiratory Medicine Author(s): Ian D Pavord, Sally Lettis, Antonio Anzueto, Neil Barnes Background Inhaled corticosteroids are important in the management of chronic obstructive pulmonary disease (COPD), but can slightly increase the risk of pneumonia in patients with moderate-to-severe COPD. Patients with circulating eosinophil counts of 2% or more of blood leucocytes respond better to inhaled corticosteroids than do those with counts of less than 2% and it was therefore postulated that blood eosinophil count might also have an effect on the ri...
Source: The Lancet Respiratory Medicine - July 24, 2016 Category: Respiratory Medicine Source Type: research
A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma
Conclusions:
FP/FORM improved lung function and measures of asthma control with comparable efficacy to FP/SAL, and demonstrated a favourable safety and tolerability profile in children aged 4–12 years. (Source: Therapeutic Advances in Respiratory Disease)
Source: Therapeutic Advances in Respiratory Disease - July 19, 2016 Category: Respiratory Medicine Authors: Emeryk, A., Klink, R., McIver, T., Dalvi, P. Tags: Original Research Source Type: research
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Abstract
Benefits of triple therapy with a long-acting muscarinic antagonist (LAMA), added to inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA), have been demonstrated. Limited data assessing the efficacy of the LAMA umeclidinium (UMEC) added to ICS/LABA are available. The aim of this study is to evaluate the efficacy and safety of UMEC added to ICS/LABAs in patients with moderate-to-very-severe COPD. This is a multicentre, randomised, double-blind, parallel-group study. Patients were symptomatic (modified Medical Research Council Dyspnoea Scale score ⩾2), despite receiving ICS/LABA (fluticason...
Source: Primary Care - June 25, 2016 Category: Primary Care Authors: Sousa AR, Riley JH, Church A, Zhu CQ, Punekar YS, Fahy WA Tags: NPJ Prim Care Respir Med Source Type: research
IL-17A synergistically stimulates TNF-α-induced IL-8 production in human airway epithelial cells: A potential role in amplifying airway inflammation.
CONCLUSIONS: IL-17A in the combination with TNF-α or IL-1β showed a synergistic augmenting effect on IL-8 and GM-CSF production in human airway epithelial cells.
PMID: 27269887 [PubMed - as supplied by publisher] (Source: Experimental Lung Research)
Source: Experimental Lung Research - June 10, 2016 Category: Respiratory Medicine Tags: Exp Lung Res Source Type: research
Efficacy and Safety of Salmeterol/fluticasone Combination Therapy in Infants and Preschool Children with Asthma Insufficiently Controlled by Inhaled Corticosteroids
Conclusions: SFC50 improved nighttime sleep disorder score and other efficacy outcome measures with no safety concerns. The results suggest that SFC50 treatment is useful to control the mild-to-moderate asthma in infant and preschool-aged children.[...]© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Abstract | Full text (Source: Drug Research)
Source: Drug Research - June 5, 2016 Category: Drugs & Pharmacology Authors: Yoshihara, S.Fukuda, H.Tamura, M.Arisaka, O.Ikeda, M.Fukuda, N.Tsuji, T.Hasegawa, S.Kanno, N.Teraoka, M.Wakiguchi, H.Aoki, Y.Igarashi, H.Terada, A.Hasegawa, M.Manki, A. Tags: Original Article Source Type: research
Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis
Conclusions
In patients with COPD with a history of exacerbations, those with greater blood eosinophils or a lower smoking history may benefit more from ICS/LABA versus LABA alone as measured by a reduced rate of exacerbations. In terms of eosinophils, this finding is consistent with findings from other studies; however, the validity of the 2.4% cut-off and the impact of smoking history require further investigation.
Trial registration numbers
NCT01009463; NCT01017952; Post-results. (Source: BMJ Open)
Source: BMJ Open - May 31, 2016 Category: Journals (General) Authors: Hinds, D. R., DiSantostefano, R. L., Le, H. V., Pascoe, S. Tags: Open access, Epidemiology, Evidence based practice, Patient-centred medicine, Respiratory medicine Research Source Type: research
Fluticasone Furoate and vilanterol trifenatate combination therapy for the Treatment of Asthma.
Authors: Gray EL, Chang V, Thomas PS
Abstract
INTRODUCTION: Combination inhaled corticosteroids (ICS) and long acting β2-adrenoceptor agonists (LABA) are used in a stepwise fashion for patients whose asthma is not controlled by low dose ICS alone. Adherence is one of the main issues facing clinicians in the control of asthma symptoms with currently available combination inhalers requiring twice-daily (BD) inhalation. Fluticasone furoate (FF) and vilanterol trifenatate (VI) both have prolonged retention in the lung with effects on lung function over 24-hours and as such the combination has been proposed fo...
Source: Expert Review of Respiratory Medicine - May 27, 2016 Category: Respiratory Medicine Tags: Expert Rev Respir Med Source Type: research
